Bedrijfsoverzicht
NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical enterprise dedicated to the development of therapeutic interventions for intracranial malignancies. The company operates within the Healthcare sector, specifically in the Biotechnology industry, where it focuses on advancing novel molecular candidates through clinical trials rather than manufacturing or commercializing products at scale. According to the most recent data, NeOnc Technologies Holdings, Inc. maintains a market capitalization of $133.32M, generates an annual revenue of $39,990, and employs a workforce of 5 individuals. These valuation and revenue figures indicate that the company operates with a very small operational footprint relative to its market cap, suggesting a capital-intensive development phase where the primary asset value lies in intellectual property and ongoing research rather than current sales volume.
Financiële gezondheid
The company reported a revenue of $39,990 over the trailing twelve months, yet recorded a net income of -$62,146,208, revealing a severe structural disconnect where costs significantly exceed all generated income. Although the company reports a free cash flow of $5.71M, this figure must be interpreted with caution given the massive negative net income, as cash flow does not necessarily equate to profitability when accounting for non-cash expenses or significant losses recorded in the period. The gross margin stands at 100.0%, indicating that the cost of goods sold is negligible relative to revenue, while the operating margin of -145637.5% and profit margin of 0.0% highlight extreme inefficiencies or one-time charges impacting the bottom line. In terms of liquidity, the company holds cash of $58,729 against total debt of $6.31M, resulting in a debt-to-equity ratio that is listed as N/A and a current ratio of 0.07, which indicates a severe inability to cover short-term liabilities with short-term assets. The return on equity is N/A due to the negative equity base, while the return on assets is -1166.5%, signaling that the company's assets are generating substantial losses rather than returns.
Waarderingsbeoordeling
Valuation metrics for NeOnc Technologies Holdings, Inc. present a complex picture with a P/E Ratio (TTM) listed as N/A and a forward P/E of -3.68, implying that the market is pricing in negative earnings growth or that traditional earnings-based valuation methods are currently inapplicable. The price-to-book ratio is calculated at -6.74, which suggests the company's market value is significantly below its book value, a scenario common in biotechnology firms with negative retained earnings. Alternative valuation multiples such as the price-to-sales ratio of 3333.88 and an EV/EBITDA of N/A further underscore the speculative nature of the investment, where the price is detached from current sales performance. The stock has traded between a 52-week low of $3.20 and a 52-week high of $12.99, meaning the current valuation sits within a range that has seen significant volatility over the past year. The beta value is listed as N/A, preventing a direct assessment of the stock's volatility relative to the broader market index based on the provided data points.
Growth & Income
NeOnc Technologies Holdings, Inc. experienced a revenue growth of -100.0% year-over-year, while earnings growth is N/A, indicating a complete cessation of revenue generation compared to the prior period rather than a slowing growth rate. Since the company does not distribute dividends, the dividend yield is N/A and the payout ratio is 0.0%, meaning the company retains all available capital for research and development rather than returning value to shareholders through cash distributions. The absence of a dividend yield combined with the massive negative net income and declining revenue suggests that the company is in a preservation or early-stage development mode where cash reserves are being utilized to fund clinical trials for lead products like NEO100 and NEO212. Overall, the growth and income profile is characterized by a total loss of revenue, a lack of profit generation, and a reliance on existing cash balances to fund operations without any current income distribution mechanisms.